Q-omics provides the consensus-scored TUBGCP4 profile across patient tissues and cancer cell-line models. TUBGCP4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, TUBGCP4 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TUBGCP4 RNA expression shows 20,592 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, COAD, and ACC as cancer lineages where TUBGCP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBGCP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBGCP4 survival associations across molecular data types. TUBGCP4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBGCP4 RNA expression–survival associations across cancer types. High TUBGCP4 expression shows unfavorable associations in PAAD, KICH, STAD and LIHC, but favorable associations in KIRC and READ. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify PAAD as the clearest survival context for TUBGCP4 RNA expression.
This table summarizes TUBGCP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TUBGCP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBGCP4 shows lower tumor expression in THCA and higher tumor expression in COAD, BLCA, HNSC, LIHC and STAD. The COAD box plot shows higher TUBGCP4 RNA expression in tumor versus normal tissue (log2 FC = +0.558, t-test p < 0.001).
This table shows molecular features associated with TUBGCP4 in patient tissues and cancer cell lines. In patient samples, TUBGCP4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBGCP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
